Search
Search
{{#data.error.root_cause}}
{{/data.error}}
{{^data.error}}
[{{{type}}}] {{{reason}}}
{{/data.error.root_cause}}
{{#data.hits.hits}}
{{#_source.featured}}
FEATURED
{{/_source.featured}}
{{#_source.showImage}}
{{#_source.image}}
{{/_source.image}}
{{/_source.showImage}}
{{/data.hits.hits}}
{{{_source.title}}} {{#_source.showPrice}} {{{_source.displayPrice}}} {{/_source.showPrice}}
{{#_source.showLink}} {{/_source.showLink}} {{#_source.showDate}}{{{_source.displayDate}}}
{{/_source.showDate}}{{{_source.description}}}
{{#_source.additionalInfo}}{{#_source.additionalFields}} {{#title}} {{{label}}}: {{{title}}} {{/title}} {{/_source.additionalFields}}
{{/_source.additionalInfo}}Anti-ASyM-biotinylated | Mouse anti-human alpha synuclein N-terminal
(Cat#: AS13 2719B)
Description
- Immunogen: Synthetic peptide derived from human alpha-synuclein N-terminal Met1-Val15
- Host: Mouse
- Clonality: Monoclonal
- Purity: Immunoglobulin affinity purified in PBS pH 7.4.
- Format: Lyophilized
- Quantity: 50 µg
- Reconstitution: For reconstitution add 50 µl of sterile water
- Storage: For short time storage add sodium azide and store at +4°C. For long time storage store lyophilized/reconstituted at -20°C; once reconstituted make aliquots to avoid repeated freeze-thaw cycles. Please remember to spin the tubes briefly prior to opening them to avoid any losses that might occur from material adhering to the cap or sides of the tube.
- Tested applications: ELISA (ELISA)
- Recommended dilutions: 2-4 µg/ml (ELISA capture)
- Expected | apparent MW: 14 kDa
- Confirmed reactivity: Human
- Not reactive in: No confirmed exceptions from predicted reactivity are currently known
- Alpha-synuclein is normally an unstructured soluble protein that can aggregate to form insoluble fibrils in pathological conditions characterized by Lewy bodies, such as Parkinson's disease, dementia with Lewy-bodies, and multiple system atrophy. In analogy to many other amyloid associated disorders, alpha-synuclein may also form oligomeric assemblies. These small and soluble forms have been suggested to exert a stronger tissue damaging effect as compared to the monomeric and fibrillar counterpart. Using a recently developed technique a monoclonal oligomer-specific antibody has been designed.
- This antibody is biotinylated.Cross reactivity of this antibody to synuclein beta was not determined.
